

HUMBERTO RUBIO & CIA.

ABOGADOS

Cra. 7 # 74 - 64 Oficina 506
Tel: (571) 3132408 - 3132423 - 3132410 - 3131759
Fax: (571) 3131647 - 3132367
E-mail: mail@rubiolawyers.com
Apartado Aereo 21848
Bogota, D.C. - Colombia

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 09-083584- -00002-0000

Fecha: 2009-10-09 14:47:51 Dep: 2020 NUECREACION
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 329 CTOINFORMACION Folios: 1

Señores

SUPERINTENDENCIA DE INDUSTRIA Y COM

División de Nuevas Creaciones

E. S. D.

REF: Expediente:
Patente de Invención:

09-083584
**DISPOSITIVO DE AJUSTE EN
HERRAMIENTAS MANUALES DE
CORTE**

Solicitud Internacional No.: PCT/ES2008/000042

Titular: BELLOTA HERRAMIENTAS, S.A.

RESPUESTA REQUERIMIENTO ARTICULO 39

HUMBERTO RUBIO CAMACHO, mayor de edad, domiciliado en Bogotá, D.C., identificado con la cédula de ciudadanía número 17.192.062 de Bogotá, abogado en ejercicio, portador de la Tarjeta Profesional No. 50.007 expedida por el Consejo Superior de la Judicatura, actuando en carácter de **APODERADO** de la Sociedad **BELLOTA HERRAMIENTAS, S.A.** domiciliada en Urola 10, E-20230, Legazpia (Guipúzcoa), España; encontrándome dentro del término legal para dar contestación al auto proferido por su Despacho mediante Oficio No. 11094 notificado por fijación en lista el 2 de Octubre de 2009, me permito anexar:

- 1- Original del Documento de Cesión otorgado por los Inventores, debidamente legalizado por el sistema de Apostille; por medio del cual se cede todos los derechos poseídos sobre la presente invención a favor de mi representada la Sociedad **BELLOTA HERRAMIENTAS, S.A.**

Teniendo en cuenta que los documentos solicitados han sido aportados dentro del término legal, en forma respetuosa solicito continuar con el trámite correspondiente.

Teniendo en cuenta lo anterior solicito se continúe con el trámite correspondiente.

Atentamente,

HUMBERTO RUBIO CAMACHO
C.C. 17.192.062 de Bogotá
T.P. 50.007 Consejo Superior
de la Judicatura.
COD. 4134



US006845777B2

(12) **United States Patent**
Pera

(10) Patent No.: **US 6,845,777 B2**
(45) Date of Patent: **Jan. 25, 2005**

(54) **COMPOSITION TO REDUCE OR QUIT
SMOKING ADDICTION**

(76) Inventor: **Ivo E. Pera, 1400 St. Charles Place,
Pembroke Pines, FL (US) 33026**

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/261,541**

(22) Filed: **Sep. 30, 2002**

(65) **Prior Publication Data**

US 2003/0084912 A1 May 8, 2003

(30) **Foreign Application Priority Data**

Oct. 22, 2001 (EP) 01125054

(51) Int. Cl.⁷ **A24F 47/00; A24B 15/00**

(52) U.S. Cl. **131/270; 131/352; 131/347**

(58) Field of Search **131/270, 359,
131/352, 347, 353, 356; 514/343; 424/400,
439, 451, 489**

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,055,478 A 10/1991 Cooper et al.

5,158,771 A 10/1992 Spindler et al.
5,656,255 A * 8/1997 Jones 424/43
5,845,647 A * 12/1998 O'Donnell, Jr. et al. 131/276
6,082,368 A 7/2000 Brown
6,138,683 A * 10/2000 Hersh et al. 131/347
6,470,894 B2 * 10/2002 Hersh et al. 131/334

* cited by examiner

Primary Examiner—Dionne A. Walls

(74) Attorney, Agent, or Firm—Daniel S. Polley, P.A.

(57) **ABSTRACT**

A method and composition to help persons reduce or quit smoking is disclosed, employing raw tobacco leaves, or tobacco fluid extract, or food grade tobacco like flavor and aroma, and Antioxidants, with or without and SAME and caffeine. All ingredients can be in a micro-powdered or liquid form, for buccal administration. The composition can be in a tablet or capsule that is intended to be slowly sucked and dissolved in the mouth, and that delivers the nicotine, caffeine or SAME, proved to be effective in alleviating smoking withdrawal symptoms. The composition can also be embedded inside a soft squeezable plastic cigarette for simulated smoking, providing additional periodic doses of nicotine, caffeine and SAME to satisfy cravings for cigarettes.

27 Claims, No Drawings

13

involving micro-encapsulation techniques. Another particular feature of the Tobacco-Antioxidants composition is to be not only several time more, effective of tobacco chewing gum in slowing the release of flavor, but it delivers a continuous rich, full and true flavor for a long period of time, exceeding skilled several fold any gum composition heretofore known to those skilled in the art. The Tobacco-Antioxidants composition can be used over a prolonged period of time without noticeable toxic or harmful effects. With the Tobacco-Antioxidants composition smokers at last have available a safe, partial substitute for conventional cigarettes.

Another object of the present invention is to provide a novel method to reduce or eliminate tobacco smoking habit, as well as the Nicotine dependency associated with that habit. The method includes the step of gradually decreasing tobacco consumption over several weeks until no further tobacco is desired. In brief, the smoker should record the time, during which each cigarette is consumed during the day, thereby reflecting his or her tobacco consumption pattern. Then after, the smoker gradually should decrease steadily the number of cigarettes to be smoked during the day. The best results are obtained if the reduction is at least one (1) cigarette per each succeeding weeks. For a smoker who consumes approximately thirty (30) cigarettes per day, the present method to reduce smoking at least 50% or more after thirty (30) to sixty (60) weeks. Starting from the first day the Tobacco-Antioxidants compound under subject is gradually ingested by the smoker and slowly chewed during the day with an increasing dose as a substitute for all cigarettes not smoked.

This serves to greatly reduce the intense craving, restlessness and irritability of the individual. As a result, the individual's confidence in breaking the stopping habit and the associated nicotine dependence grows. Since the tobacco consumption is decreased gradually there is less a trauma for the individual, such as anxiety, irritability or other adverse symptoms are reduced to a minimum.

Like nicotine, caffeine is found naturally in plants like tea, coffee, kola nuts, and cacao beans (from which cocoa and chocolate are made). In fact, it is even placed in the same general chemical class as nicotine. Dried ripe seeds of coffee are the source of caffeine (approximately or about 0.7 to approximately or about 2%) In humans, caffeine, 1,3,7-trimethylxanthine, is demethylated into three primary metabolites: theophylline, theobromine and paraxanthine. Since the early part of the 20th century theophylline has been used in therapeutics for bronchodilatation, for acute ventricular failure and for long-term control of bronchial asthma.

Caffeine ($C_8H_{10}N_4O_2$) is used orally as a mild CNS stimulant to aid in staying awake and to restore mental alertness in fatigued patients. It stimulates all levels of the central nervous system. In oral doses of about 100 to about 200 mg., it stimulates the cerebral cortex producing a more rapid and clear flow of thought, wakefulness or arousal in fatigued patients and improved by psychomotor coordination. Its cortical effects are milder and of shorter duration than those of amphetamines. In slightly larger doses, caffeine stimulates medullary vagal, vasomotor and respiratory centers, including bradycardia, vasoconstriction and an increased respiratory rate.

Caffeine exerts multiple effects on the heart. It has a positive inotropic effect on the myocardium and a positive chronotropic effect on the sinoatrial node; causing a transient increase in heart rate, force of contraction, cardiac output

14

and work of the heart. In doses of excess of about 250 mg. the centrally mediated vagal effects of caffeine may be masked by increased sinus rates, tachycardia, extrasystoles or other ventricular arrhythmias may result. Caffeine constricts the cerebral blood vessels but directly dilates peripheral blood vessels; thus, it decreases peripheral vascular resistance. The effect of this decrease in vascular resistance on blood pressure is compensated for by increased cardiac output. Thus the overall effect of caffeine on heart rate and blood pressure is dependent on whether the central nervous system or peripheral effects predominate. In most instances, therapeutic doses of caffeine increase blood pressure only slightly.

Other pharmacological effects of caffeine include the following:

stimulate voluntary skeletal muscle, increasing the force of muscle contraction and decreasing muscular fatigue; they stimulate parietal cells, increasing gastric acid and secretion; they induce a mild diuresis by increasing renal blood flow and glomerular filtration rate and decreasing proximal tubular re-absorption of sodium and water; and stimulate glycolysis and lipolysis, but the increases in blood glucose and plasma lipids usually are not significant in normal patients.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The invention provides an effective antismoking Tobacco-Antioxidants composition which can consist of tobacco leaves or Tobacco flavor, and various antioxidants (listed earlier in this disclosure), with or without caffeine and SAME, and other ingredients for administration in unit dosage form, such as chewing gums, tablets, capsules, pills, powders, granules, liquid solutions micro-encapsulated or in suspensions. For oral administration, either solid or fluid unit dosage forms can be prepared, but most preferable in capsule or chewable tablet. A provision of the invention is also the provision to use the present composition in a liquid form embedded inside a soft squeezable plastic cigarette for simulated smoking.

It is well known to entrap in bulk polymers or microcapsules to attain controlled sustained release of a permeant. Examples may be found in my U.S. Pat. No. 4,906,488 which is incorporated herein by reference. Therefore, another innovative feature of the Tobacco-Antioxidants composition involves the utilization of my Micro-Imbibed Polymer-Flavor Sponge technology to overcome the disadvantage found in a chewable gum or tablet available on the market (i.e. that when chewed the initial perception of the flavor contained in, appear at a low after a minute or more, that increase and after four or five minutes of chewing the flavor intensity drop to an uninteresting level to slowly disappear). With my process the tobacco flavor and other ingredients added to the Tobacco-Antioxidants compound provide an almost instantaneous tobacco flavor release with an extended high intensity constant, continuous uninterrupted tobacco flavor perception time and with evenly and uniformly controlled release of all active ingredients over an extended period of time.

Such method, moreover substantially reduces, the diffusion rate, volatility or susceptibility to oxidation or other form of environmental attack upon the tobacco or other flavor, and is effective in lengthening the shelf life of the composition by preserving the entire composition for a longer period of time.

For preparing solid compositions such as tablets, the principal active ingredient is mixed with conventional ingre-

US 6,845,777 B2

17

for purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise form disclosed. Obvious modifications or variations are possible in light of the above teaching. For example, various phases of the method may be adjusted in length in order to reflect differences in the smoking patterns of the individual.

The Tobacco-Antioxidants Compound was chosen and described to provide the best illustration of the principles of this invention and its practical application to thereby enable one of ordinary skill in the art to utilize the invention in various embodiments and with various modifications as are suited to the particular use contemplated. All such modification and variations are within the scope of the invention as determined by the appended claims when interpreted in accordance with the breadth to which they are fairly, legally and equitably entitled. As set forth the single ingredients of the Tobacco-Antioxidants Compound object of this invention are more effective when taken all together, nevertheless each of the ingredients can be used singularly concurrently with the use of tobacco.

Although the present invention has been described in a practical and possibly preferred form, it is to be understood that departures may be made therefrom within the scope of the present invention which is not to be limited to the details disclosed herein, but is to be accorded the full scope of the appended claims so as to embrace any and all equivalent compositions and methods. The suggested method of eliminating an individual's tobacco smoking habit and associated nicotine dependence in regulated matter, of course comprising the step of:

breaking a day down into smoking periods;
recording the number of cigarettes smoked;
reducing weekly the number of cigarettes smoked;

administering the dosage of the Tobacco-Antioxidants compound as alternative replacement of a cigarette, to gradually decreasing the amount of cigarettes to be gradually decreasing the amount of cigarettes to be gradually decreasing the amount of cigarettes to be smoked, while if necessary increasing the administration of the Tobacco-Antioxidants composition until the nicotine, the caffeine or SAME administrations and smoking habit has been successful reduced or cured.

The invention can have the following characteristics:

1. A composition to help persons reduce or quit tobacco smoking, which comprises a Tobacco-Antioxidants formulation, with or without raw uncured tobacco in powdered form or tobacco fluid extract or a food grade tobacco like aroma and flavors, or SAME and Caffeine, which can include as main ingredient Antioxidants derived from one or more amino acids, enzymes, chemicals, hormones, plants extracts, proteins, and when slowly dissolved in the mouth it gives a dose of nicotine almost equal to a cigarette, suitable for oral administration.
2. Composition of characteristic 1 that can be administered orally and is effective in preventing or curtailing very early stage diseases, in tobacco smokers.
3. Composition of characteristic 1 where the ingredients for administration are in unit dosage form, such as chewing gums, tablets, capsules, pills, powders, granules, liquid solutions or suspensions.
4. Composition of characteristic 1 where the composition can be used embedded inside a soft squeezable plastic cigarette for simulated smoking.
5. Composition of characteristic 1 where the composition can be prepared by employed conventional organic or inorganic additives and flavors.

18

6. Composition of characteristic 1 where the flavor can be preferably tobacco and the additives can be an excipient, a preservative, a stabilizer, a suspending agent, a dispensing agent, a diluent and/or a base wax.

7. Composition of characteristic 1 where the tobacco can be in liquid flavor or in liquid or powdered form and one or more antioxidants with or without other ingredients or additives and flavors.

8. Composition of characteristic 1, where the antioxidant(s) can be selected from one or more of the following Antioxidants: Acetyl-L-Carnitine, Adenosine, Allicin, Aloe, Alpha Lipoic Acid, BHA, BHT, Bilirubin, Capsaicin, Catalases, Catechin, Cysteine, Coenzyme Q10, Copper Sebacate, Coumarin, Curcumin, Dimethylglycine, Glycine, Ferrous Fumarate, Folic Acid, Genistein, Ginger, Ginkgo Biloba, Gallates, Gluconate, Glutathione or Glutathione Peroxidase, Green Tea, Inositol, Isoascorbic Acid, L-Glutamine, Linoleic Acid, L-Methyl Methionine, L-Seleno Cysteine, L-Seleno Methionine or Methionate, Lycopene, Lutein, Manganese, Melatonin, Methionine Reductase w/(Cu—Zn or Mn), N-Acetylcysteine or L-Cysteine, N-Acyl 1-Cysteine Esters, N-Acyl 1-Methionine Esters, Poplar Bud, Procyanidin, Pycnogenol, Resveratrol, Rosemary, Rutin, Rutinose, Selenium-Yeast, Seleno Cysteine, Seleno Methionine or Methionate, Silybum Marianum, Sodium Bisulfite, Sodium Metasulfite, Sodium Sulfite, Sodium Thiosulfite, Spirulina, Sulfuraphane, Superoxide Dismutase (SOD), Taurine, Thioglycerol, Thiol, Thiosorbitol, Thiourea, Vitamin A compounds, Vitamin B2 compounds, Vitamin B6 compounds, Vitamin B12 compounds, Vitamin C compounds, Vitamin E compounds, Wheat Grass and/or Zinc Gluconate.

9. Composition of characteristic 1 where the composition contains *Nicotiana tabacum* leaves reduced in a dry powdered form, which contain between about 2% to about 8% of Nicotine.

10. Composition of characteristic 1 where the composition contains tobacco fluid extract with or without nicotine.

11. Composition of characteristic 1 where the composition contains Food Grade Tobacco like Aroma and Flavor and sugar.

12. Composition of characteristic 1 where the S-Adenosyl-L-Methionine (SAME) aids in the production of the master oxidant Glutathione, which is a bona-fide treatment for diseases at their source, of which each dose preferably does not exceed about 200 mg, though such value is not considered limiting.

13. Composition of characteristic 1 where the Caffeine acts as a central stimulant, of which each dose preferably does not exceed 100 mg, though such value is not considered limiting.

14. Composition of characteristic 1 wherein in liquid form it can contain water, soft drink and/or fruit juices.

15. Composition of characteristic 1 wherein in liquid form it can contain beer, coffee, chocolate and/or alcoholic drink.

16. Composition can comprise the following percentages: (1) from about or approximately 1% to about or approximately 85% by weight (and all numerical ranges therebetween) of one or more Antioxidants substance; (2) from about or approximately 1% to about or approximately 65% by weight (and all numerical ranges therebetween) of tobacco leaves; (3) from about or approximately 0.01% to about or approximately 5% by weight (and all numerical ranges therebetween) caffeine; and (4) from about or approximately 0.01% to about or

COLOMBIA

CESIÓN

ASSIGNMENT

Los que suscriben

The undersigned

José María AZPEITIA URRESTARAZU

Domiciliado en

with domicile at

Urola, 10, E-20230 LEGAZPIA (GUIPÚZCOA), España

(en adelante llamada el(los) CEDENTE(S)),
declara(n) bajo juramento ser único(s) y verdadero(s) inventor(es)
de la invención titulada

(hereinafter referred to as the ASSIGNOR(S))
State(s) under oath to be the sole and true inventor(s) of
the invention titled

DISPOSITIVO DE AJUSTE EN HERRAMIENTAS
MANUALES DE CORTE

(en adelante llamada la INVENCION)

(hereinafter referred to as the INVENTION)

declara(n) por el presente instrumento que cede(n), sin reservas ni
limitaciones, a

declare(s) by this document that he/she/they assign(s)
without reservations or limitations, unto

BELLOTA HERRAMIENTAS, S.A.

sociedad organizada y existente bajo las leyes de España , y
domiciliada en

a company organized and existing under the laws of Spain,
and domiciled at

Urola, 10, E-20230 LEGAZPIA (GUIPÚZCOA), España

todos los derechos inherentes a dicha invención y que la citada
sociedad queda facultada para solicitar en su nombre la patente
correspondiente en la República de Colombia.

all rights inherent to said invention and that the above
mentioned company hereby is entitled to apply, in its own
name, for the corresponding patent in the Republic of
Colombia.

CEDENTE(S)

Firmado en , a

ASSIGNOR(S)

Signed at , on



x



Firma(s)/Signature(s)

Nombre de cada firmante / José María AZPEITIA URRESTARAZU

Name of each Signor

*This document requires Notarization and legalization by Apostille.
Este documento requiere Notarización y legalización mediante Apostilla.*

37
LEGI - 2

TIMACION.- Yo, DON ANTONIO-PEDRO MULA SOTO, Notario del Ilustre Colegio Notarial del País Vasco, con residencia en esta villa. -----


DOY FE: De la **AUTENTICIDAD** de la firma que antecede de Don Jose María Azpeitia Urrestarazu con DNI 15882844X, por haber sido puesta en mi presencia en el presente documento. -----

La presente legitimación de firma está amparada en el Acta número 1327 de mi Protocolo, a la que incorporo fotocopia del presente documento. -----

Zumarraga, a 10 de Septiembre del 2009. -----



REF. LIBRO INDICADOR Nº 677/09/SR 2



El presente folio es el agregado al documento en el que figura la firma de D. ANTONIO PEDRO MULA SOTO, Notario de Zumárraga, estampada en folio de papel común, al pie de testimonio de legitimación expedido con fecha 10 de septiembre de 2009, bajo el número 677 de su Libro Indicador.

APOSTILLE

Convention de la Haye du 5 octobre 1961

- 1.- País: España
El presente documento público
- 2.- ha sido firmado por D. ANTONIO PEDRO MULA SOTO
- 3.- Actuando en calidad de NOTARIO
- 4.- Se halla sellado/timbrado con el sello de su Notaría

CERTIFICADO

- 5.- en DONOSTIA-SAN SEBASTIAN 6.- el día 30 de Septiembre de 2009
- 7.- por Dña. GUADALUPE MARIA INMACULADA ADANEZ GARCIA,
Delegada de la Junta Directiva del Ilustre Colegio Notarial del País Vasco
- 8.- con el Número 2342/09
- 9.- Sello/timbre
- 10.- Firma



SELO DE
LEGITIMACIONES Y
LEGALIZACIONES



Handwritten signature of D. Antonio Pedro Mula Soto.





2020
Bogotá D.C.,

Doctor(a)
RUBIO CAMACHO HUMBERTO
Apoderado(a) y/o Representante de
BELLOTA HERRAMIENTAS, S.A.

REFERENCIA	Radicación No.	9 83584
	Solicitud internacional	PCT/ES2008/000042
	Fecha inicio fase nacional	16/09/2009
	Trámite	11
	Evento	378
	Actuación	416
	Oficio No.	10310
	Folios	1

Teniendo en cuenta que la solicitud de privilegio de patente que se tramita bajo el expediente indicado en la referencia, reúne los requisitos de forma establecidos en la Decisión 486 de la Comisión de la Comunidad Andina, el Tratado de Cooperación en Materia de Patentes (PCT), el Reglamento y la Circular Única de la Superintendencia de Industria y Comercio, se envía el extracto de la solicitud a la Oficina de Comunicaciones para efecto de su publicación en la Gaceta de Propiedad Industrial.

Cúmplase
Dado en Bogotá DC,

16 ABR. 2010

ALIX CARMENZA CESPEDES DE VERGEL
Directora de Nuevas Creaciones (c)

jfernand